XWXuan Wu

Xuan Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xuan Wu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Jinhu Wang

    Department of Surgical Oncology, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China

    2 shared publications
  • Lifeng Zhang

    Department of Oncology Surgery, Children’s Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China

    2 shared publications
  • Dongfang Lu

    Department of Oncology Surgery, Children’s Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China

    1 shared publication
  • Jiabin Cai

    Department of Surgical Oncology Children's Hospital Zhejiang University School of Medicine National Clinical Research Center for Child Health Hangzhou China

    1 shared publication
  • Jiabin Cai

    Department of Surgical Oncology, Children’s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents’ Health and Diseases, Hangzhou, China

    1 shared publication
  • Jieni Xiong

    Department of Oncology Surgery, Children’s Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China

    1 shared publication

Latest Publications

  • Open Access

    Laparoscopic Surgery for Pediatric Malignant Ovarian Germ Cell Tumors After Neoadjuvant Chemotherapy: A Single-Center Retrospective Study

    by Jiabin Cai, Jieni Xiong, Xuan Wu, Min He, Lifeng Zhang, Dongfang Lu, Junqing Mao, Linjie Li, Yinbing Tang, Zheyu Ding, et al.

    Purpose: The purpose of this study was to evaluate the clinical effects and safety for cancer treatment of neoadjuvant chemotherapy (NACT) when combined with laparoscopic fertility-sparing (anatomical preservation) surgery in pediatric patients who have large malignant ovarian germ cell tumors (MOGCTs). Methods: We performed a retrospective analysis on seven young female patients with a median age of 8.8 years (range: 10 months to 13.4 years). The patients were treated between 2015 and 2023, and all of them received two to three cycles of JEB (carboplatin, etoposide, and bleomycin) regimen as NACT. After the NACT, these patients had laparoscopic (n = 7) unilateral salpingo-oophorectomy. Results: Neoadjuvant chemotherapy (NACT) achieved a median reduction in tumor volume of 91% (range: 85% to 97%). All the procedures were completed successfully and there was no need to convert to open surgery. The median operative time was 85 min (range: 70 to 120 min), and the blood loss was minimal. The median blood loss was 10 mL, with a range of 5 to 50 mL. In patients with yolk sac tumors, alpha-fetoprotein (AFP) levels returned to normal within a median of 20 days after the operation. With a median follow-up of 54 months (range: 18 to 118 months), all the patients had 100% disease-free survival. Conclusions: This study suggests that NACT combined with laparoscopic fertility-sparing (anatomical preservation) surgery may be effective and appears promising for selected pediatric patients with MOGCTs.

  • Open Access

    Robotic liver resection for hepatic focal nodular hyperplasia in children: comparison with open surgery

    by Xuan Wu, Min He, Yinbing Tang, Ming Chen, Jiabin Cai, Lifeng Zhang, Yuwei Wang, Ting Tao, Jinhu Wang

    Background: Robot-assisted surgery is becoming increasingly used in pediatric oncology. The present study aimed to evaluate the feasibility and safety of robotic liver resection (RLR) for hepatic focal nodular hyperplasia (FNH) in children and compare surgical outcomes between RLR and open liver resection (OLR). Methods: Pediatric patients with liver FNH undergoing lesion resection between January 2020 and June 2024 were included in the study. Patient demographics, operative details, postoperative outcomes, and follow-up were recorded and analyzed. Results: A total of 20 patients were included in this study. Twelve patients underwent RLR and eight underwent OLR. In the RLR group, the median age was 93.1 months (range, 28–134 months) with a median weight of 32.4 kg (range, 9.7–80 kg). The median maximum tumor diameter at operation was 62.6 mm (range, 49–80 mm) and the median tumor volume was 94.3 mL (range, 35–254.1 mL). Operative time was 168.5 min (range, 116–245 min), intraoperative blood loss was 23.3 mL (range, 5–50 mL) and the length of postoperative hospital stay was 5.7 days (range, 4–11 days). There was a significant difference ( p vs. 137.6 months), maximum tumor diameter (62.6 mm vs. 98 mm), tumor volume (94.3 mL vs. 496.2 mL), operative time (168.5 min vs. 281.4 min), blood loss (23.3 mL vs. 288.7 mL), and length of postoperative hospital stay (5.7 days vs. 9.5 days). There was a borderline significant association between surgical approach (RLR/OLR) and fluctuation in the magnitude of Alanine aminotransferase (ALT) (odds ratio=0.004, 95% confidence interval: 0.000 to 1.096, p =0.05). Conclusions: Our initial experience suggested that RLR for hepatic FNH in children was both feasible and safe. Tumors in the RLR group were significantly smaller than the OLR group: it proved possible to excise tumors larger than 250 mL in volume.